|12.26||+0.0500||+0.41%||Vol 1.92M||1Y Perf 17.63%|
|Sep 22nd, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||15.38||Analyst Rating||Strong Buy 1.25|
|Potential %||25.45||Finscreener Ranking||★ 40.37|
|Insiders Trans % 3/6/12 mo.||-100/-100/-78||Value Ranking||★ 37.80|
|Insiders Value % 3/6/12 mo.||-100/-100/-98||Growth Ranking||★ 34.60|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-98||Income Ranking||— -|
|Price Range Ratio 52W %||63.20||Earnings Rating||Strong Buy|
|Market Cap||3.52B||Earnings Date||6th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th Nov 2023|
|Estimated EPS Next Report||-0.07|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.57M|
|Avg. Monthly Volume||1.68M|
|Avg. Quarterly Volume||1.89M|
Amicus Therapeutics Inc. (NASDAQ: FOLD) stock closed at 12.26 per share at the end of the most recent trading day (a 0.41% change compared to the prior day closing price) with a volume of 1.92M shares and market capitalization of 3.52B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 584 people. Amicus Therapeutics Inc. CEO is John F. Crowley.
The one-year performance of Amicus Therapeutics Inc. stock is 17.63%, while year-to-date (YTD) performance is 0.41%. FOLD stock has a five-year performance of 0.41%. Its 52-week range is between 9.1 and 14.1, which gives FOLD stock a 52-week price range ratio of 63.20%
Amicus Therapeutics Inc. currently has a PE ratio of -12.80, a price-to-book (PB) ratio of 24.97, a price-to-sale (PS) ratio of 13.17, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -33.63%, a ROC of -34.90% and a ROE of -116.90%. The company’s profit margin is -74.94%, its EBITDA margin is -65.70%, and its revenue ttm is $241.14 Million , which makes it $0.86 revenue per share.
Of the last four earnings reports from Amicus Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.07 for the next earnings report. Amicus Therapeutics Inc.’s next earnings report date is 06th Nov 2023.
The consensus rating of Wall Street analysts for Amicus Therapeutics Inc. is Strong Buy (1.25), with a target price of $15.38, which is +25.45% compared to the current price. The earnings rating for Amicus Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Amicus Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Amicus Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 31.11, ATR14 : 0.42, CCI20 : -169.19, Chaikin Money Flow : 0.05, MACD : -0.13, Money Flow Index : 55.95, ROC : -3.84, RSI : 39.93, STOCH (14,3) : 21.74, STOCH RSI : 0.08, UO : 49.71, Williams %R : -78.26), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Amicus Therapeutics Inc. in the last 12-months were: Bradley L. Campbell (Option Excercise at a value of $172 640), Bradley L. Campbell (Sold 79 825 shares of value $968 639 ), Campbell Bradley (Option Excercise at a value of $243 028), Campbell Bradley (Sold 133 193 shares of value $1 666 621 ), Campbell Bradley L (Option Exercise at a value of $34 398), Campbell Bradley L (Sold 11 700 shares of value $144 016 ), Crowley John (Option Excercise at a value of $798 669), Crowley John (Sold 304 946 shares of value $3 794 419 ), Crowley John F (Sold 6 044 shares of value $74 406 ), Daphne Quimi (Sold 11 923 shares of value $152 444 ), David Michael Clark (Sold 37 382 shares of value $457 179 ), Ellen S. Rosenberg (Sold 31 839 shares of value $424 006 ), John F. Crowley (Option Excercise at a value of $798 669), John F. Crowley (Sold 328 081 shares of value $4 011 081 ), Margaret G. McGlynn (Option Excercise at a value of $49 800), Margaret G. McGlynn (Sold 15 000 shares of value $195 387 ), Michael G. Raab (Option Excercise at a value of $49 800), Michael G. Raab (Sold 4 408 shares of value $49 943 ), Quimi Daphne (Sold 11 923 shares of value $152 449 ), Rosenberg Ellen (Sold 31 839 shares of value $424 095 ), Samantha Prout (Option Excercise at a value of $407 116), Samantha Prout (Sold 36 909 shares of value $517 095 ), Sblendorio Glenn (Option Excercise at a value of $49 800)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.